Low molecular weight chitooligosaccharide inhibits infection of SARS-CoV-2 in vitro

J Appl Microbiol. 2022 Aug;133(2):1089-1098. doi: 10.1111/jam.15618. Epub 2022 May 31.

Abstract

Aims: The discovery of antiviral substances to respond to COVID-19 is a global issue, including the field of drug development based on natural materials. Here, we showed that chitosan-based substances have natural antiviral properties against SARS-CoV-2 in vitro.

Methods and results: The molecular weight of chitosan-based substances was measured by the gel permeation chromatography analysis. In MTT assay, the chitosan-based substances have low cytotoxicity to Vero cells. The antiviral effect of these substances was confirmed by quantitative viral RNA targeting the RdRp and E genes and plaque assay. Among the substances tested, low molecular weight chitooligosaccharide decreased the fluorescence intensity of SARS-CoV-2 nucleocapsid protein of the virus-infected cells in a dose-dependent manner.

Conclusions: In conclusion, the chitooligosaccharide, a candidate for natural treatment, has antiviral effects against the SARS-CoV-2 virus in vitro.

Significance and impact of study: In this study, it was suggested for the first time that chitosan-based substances such as chitooligosaccharide can have an antiviral effect on SARS-CoV-2 in vitro.

Keywords: COVID-19; SARS-CoV-2; antiviral effect; chitooligosaccharide; natural treatment.

MeSH terms

  • Animals
  • Antiviral Agents / pharmacology
  • COVID-19 Drug Treatment*
  • Chitosan* / pharmacology
  • Chlorocebus aethiops
  • Molecular Weight
  • Oligosaccharides
  • SARS-CoV-2
  • Vero Cells

Substances

  • Antiviral Agents
  • Oligosaccharides
  • oligochitosan
  • Chitosan